Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Share-based Compensation: 2014-2025

Historic Share-based Compensation for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $35.8 million.

  • Ascendis Pharma A's Share-based Compensation rose 25.60% to $35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.7 million, marking a year-over-year increase of 34.88%. This contributed to the annual value of $103.4 million for FY2024, which is 44.13% up from last year.
  • Per Ascendis Pharma A's latest filing, its Share-based Compensation stood at $35.8 million for Q3 2025, which was up 5.39% from $34.0 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Share-based Compensation ranged from a high of $19.6 billion in Q2 2021 and a low of $13.6 million during Q3 2022.
  • In the last 3 years, Ascendis Pharma A's Share-based Compensation had a median value of $26.9 million in 2025 and averaged $24.7 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Share-based Compensation surged by 132,747.25% in 2021, and later crashed by 99.91% in 2022.
  • Ascendis Pharma A's Share-based Compensation (Quarterly) stood at $16.2 million in 2021, then fell by 12.54% to $14.2 million in 2022, then grew by 20.93% to $17.1 million in 2023, then surged by 63.70% to $28.0 million in 2024, then increased by 25.60% to $35.8 million in 2025.
  • Its last three reported values are $35.8 million in Q3 2025, $34.0 million for Q2 2025, and $26.9 million during Q1 2025.